BioThrust
Private Company
Funding information not available
Overview
BioThrust is a private, pre-revenue platform technology company pioneering a novel bioreactor system for cell culture. Its core innovation, the Membrane Stirrer, enables bubble-free aeration and gentle mixing, achieving unprecedented cell densities (e.g., 44 million iPSCs/mL) with low shear and no foam across various cell types. The company targets the high-growth CGT and biologics manufacturing market by offering a scalable, application-agnostic hardware solution designed to significantly reduce the cost of goods sold (COGS) for advanced therapies. BioThrust's technology has been validated in partnership with several research institutions and is progressing toward commercial scale-up.
Technology Platform
The Membrane Stirrer, a bioreactor impeller with an integrated gas-permeable membrane that enables bubble-free aeration, ultra-high gas transfer rates (10x kLa), minimal shear stress (99% reduction), and zero foaming for scalable cell culture.
Opportunities
Risk Factors
Competitive Landscape
BioThrust competes with dominant bioprocessing equipment vendors like Sartorius (BIOSTAT STR), Thermo Fisher (HyPerforma), and Cytiva (Xcellerex), whose reactors rely on sparging. It also faces niche competitors exploring alternative aeration, such as rocking-motion bioreactors (e.g., Cytiva's Wave) or other membrane-based systems. BioThrust's claimed combination of high kLa, low shear, and linear scalability in a stirred-tank format is its key differentiator.